<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap5" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>5</ChapterID>
          <ChapterNumber>Chapter 5</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_5</ChapterDOI>
          <ChapterSequenceNumber>5</ChapterSequenceNumber>
          <ChapterTitle Language="En">Androgen Receptor Biology in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>61</ChapterFirstPage>
          <ChapterLastPage>70</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_5" CorrespondingAffiliationID="Aff1_5">
              <AuthorName DisplayOrder="Western">
                <GivenName>Edward</GivenName>
                <GivenName>P.</GivenName>
                <FamilyName>Gelmann</FamilyName>
              </AuthorName>
              <Contact>
                <Email>gelmanne@columbia.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_5">
              <OrgDivision>Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center</OrgDivision>
              <OrgName>Columbia University</OrgName>
              <OrgAddress>
                <City>New York</City>
                <State>NY</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_5" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Androgens are essential development and survival factors for prostate epithelial cells. Prostate cancer cells retain androgen dependence and, for some period of time, are suppressed by androgen deprivation. Castration-resistant prostate cancer (CRPC) arises after a period of androgen withdrawal and represents the most advanced stage of the disease. CRPC is mediated by the reactivation of androgen receptor activity in the castrate patient. Androgen receptor is reactivated in CRPC by a variety of mechanisms, the breadth of which underscores the importance of androgen receptor for prostate cancer cell proliferation at all stages of the disease. Androgen receptor gene may be affected by the amplification of the locus on the X chromosome or by the activation of mutations. Androgen receptor protein may be phosphorylated by a variety of kinases to enhance its activity in the presence of subphysiologic concentrations of ligand. The cancer cells themselves may produce sufficient levels of androgenic steroids to sustain receptor activation. Androgen receptor activity may also be enhanced by the overexpression of coactivator proteins that allow the formation of the transcriptional complex after the androgen receptor binds to DNA. Lastly, androgen receptor mRNA may be subjected to alternative splicing that may generate ligand-independent truncated forms of activated androgen receptor protein. Thus CRPC cells reactivate androgen receptor as a critical pathway towards cancer progression.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Androgen receptor</Keyword>
            <Keyword>Androgen</Keyword>
            <Keyword>Mutation</Keyword>
            <Keyword>Coactivator</Keyword>
            <Keyword>p160</Keyword>
            <Keyword>Beta-catenin</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Para TextBreak="No">The androgen receptor (AR) is a member of the nuclear hormone receptor family. Androgens are essential for prostate epithelial development and sustenance. Malignant prostate epithelium retains, to some degree, the dependence on AR that characterized the normal prostate epithelium from which it arose. Early in prostate cancer development, androgens activate the <Emphasis Type="Italic">TMPRSS2</Emphasis> gene promoter that is often recombined with the <Emphasis Type="Italic">ERG</Emphasis> transcription factor gene or, less frequently, other members of the ETS family to drive the invasiveness of the majority of prostate cancers [<CitationRef CitationID="CR1_5">1</CitationRef>, <CitationRef CitationID="CR2_5">2</CitationRef>]. In advanced prostate cancer, androgen ablative therapy targets AR, but it is eventually overcome by AR reactivation in castration-resistant prostate cancer (CRPC). The reactivation of AR in CRPC occurs by a wide range of mechanisms. The molecular oncology of AR is the focus of this chapter.</Para>
          <Para TextBreak="No">Like the epithelium from which they arise, prostate cancer cells retain responsiveness to and dependence on androgens. It has been known for more than half a century that prostate cancer in most cases retains androgen responsiveness and undergoes regression in response to androgen deprivation [<CitationRef CitationID="CR3_5">3</CitationRef>, <CitationRef CitationID="CR4_5">4</CitationRef>]. Over 80% of men with disseminated prostate cancer show some clinical response to androgen ablation. Still, there is no way to predict which patients will not respond or how long the responding patients will benefit from initial androgen deprivation. Androgen responsiveness in prostate cancer does not correlate with either the presence or the levels of androgen receptor in cancer tissues [<CitationRef CitationID="CR5_5">5</CitationRef>–<CitationRef CitationID="CR10_5">10</CitationRef>].</Para>
          <Para TextBreak="No">In nearly all instances, recurrent and metastatic prostate cancer escapes from the effects of androgen ablation and becomes castration-resistant. Preclinical models of castration resistance using both hormone-dependent cultured cells and tumor lines were analyzed using expression array analysis to determine gene expression changes common to a number of different hormone-independent derivative lines. It was surprising and paradigm-setting to find that the only expression change common to androgen independence of seven different cell lines and tumors was the increased expression of AR [<CitationRef CitationID="CR11_5">11</CitationRef>]. AR overexpression alone not only conferred androgen independence to cultured cells but also sensitized cells to picomolar concentrations of androgens and conferred AR agonism to the potent anti-androgen bicalutamide.</Para>
          <Section1 ID="Sec1">
            <Heading>AR Structure</Heading>
            <Para TextBreak="No">The three-dimensional structure of the AR ligand-binding domain is similar to that of other steroid hormone receptors. Ligand binding induces conformational changes that initiate translocation from the cytoplasm to the nucleus and also allows the AR to interact with coregulator proteins that mediate transcription initiated by AR binding to its cognate DNA sequences. The coactivators play a fundamental role in the activity of AR. Alterations in the structure or levels of coactivator proteins can therefore greatly impact AR transcriptional activity. Mutations in the AR, whether hereditary or sporadic, have been implicated in the development and growth of prostate cancer. Moreover, tumor suppressors, growth factors, and their receptors may also regulate the activity of AR [<CitationRef CitationID="CR12_5">12</CitationRef>–<CitationRef CitationID="CR20_5">20</CitationRef>].</Para>
            <Para TextBreak="No">The AR is located on the X chromosome at Xq11-12 [<CitationRef CitationID="CR21_5">21</CitationRef>, <CitationRef CitationID="CR22_5">22</CitationRef>]. It is therefore a single-copy gene in males, allowing phenotypic expression of mutations without the influence of a wild-type codominant allele. Numerous spontaneous mutations of the human AR have been described, and the exploration of the effects of these mutations on AR activity has helped to elucidate the nature of the functional domains of the AR protein. Loss or attenuation of AR function results in complete or partial androgen insensitivity, respectively. Individuals who have complete androgen insensitivity syndrome are phenotypic, but sterile, females. Interestingly, they do not manifest sexual identity discordance, underscoring the fact that AR plays a role in the configuration of the male CNS as well as in morphologic development [<CitationRef CitationID="CR23_5">23</CitationRef>].</Para>
            <Para TextBreak="No">The <Emphasis Type="Italic">AR</Emphasis> gene consists of eight exons that encode a ∼2,757-base pair open reading frame within a 10.6-kb mRNA [<CitationRef CitationID="CR24_5">24</CitationRef>–<CitationRef CitationID="CR27_5">27</CitationRef>]. Like the other members of the steroid hormone receptor family of genes, the exons of the <Emphasis Type="Italic">AR</Emphasis> gene code for functionally distinct regions of the protein that correspond to the exonic organization of other steroid hormone receptor genes suggesting a modular genetic composition that facilitated gene duplication and divergence during evolution. The <Emphasis Type="Italic">AR</Emphasis> genomic organization and location on the X chromosome is conserved in mammals and may reflect a developmentally significant association of <Emphasis Type="Italic">AR</Emphasis> with other syntenic genes [<CitationRef CitationID="CR28_5">28</CitationRef>]. The first exon codes for the N-terminal domain (NTD), which serves as the transcriptional regulatory region of the protein. Exons 2 and 3 code for the central DNA-binding domain. Exons 4–8 code for the C-terminal ligand-binding domain.</Para>
            <Para TextBreak="No">Segments of the AR gene have been conserved throughout evolution, implying that these regions are critical for the activity of the molecule. The DNA-binding domain is most highly conserved across species. Other regions of the gene striking in their degree of sequence conservation include much of the hinge region and the ligand-binding domain. A large number of conserved ligand-binding domain residues that are targets for mutations, which result in androgen insensitivity syndrome, are conserved from frog to man. The NTD is encoded by the first exon and does not demonstrate a high degree of sequence conservation, from frog to rodent to human, upstream of codon 539 in the human sequence. However, the sequence comparison of AR NTDs from primates reveals that codons 1–53 and 360–429 generate conserved protein segments across a broad evolutionary spectrum [<CitationRef CitationID="CR29_5">29</CitationRef>]. These regions are important for dimerization of human AR, and their genetic conservation reflects similarity in function for primate AR molecules.</Para>
            <Para TextBreak="No">Even though the AR ligand-binding domain shares only 20% sequence similarity with other steroid hormone receptors, the three-dimensional structure resembles that of other steroid hormone receptors [<CitationRef CitationID="CR30_5">30</CitationRef>–<CitationRef CitationID="CR35_5">35</CitationRef>]. Many steroid hormone receptor ligand-binding domains fold into 12 helices, three of which form a ligand-binding pocket. When an agonist is bound, helix 12 folds over the pocket to enclose the ligand. In the unbound state or in the presence of an antagonist, helix 12 is repositioned away from the pocket in such a way that the coactivator binding is impeded [<CitationRef CitationID="CR32_5">32</CitationRef>]. There is evidence to suggest that ligand-bound AR dimerizes in vivo, suggesting that the N-terminal region of AR is important for protein dimerization [<CitationRef CitationID="CR36_5">36</CitationRef>–<CitationRef CitationID="CR38_5">38</CitationRef>].</Para>
            <Para TextBreak="No">The NTD is the primary effector region of AR and plays a key role in transactivation. Deletion of the ligand-binding domain from AR results in a residual N-terminal fragment with transcriptional activity nearly equal to that of the ligand-bound, full-length protein, suggesting that the NTD is fully capable of initiating the assembly of the transcriptional complex, including binding to AR coactivators. The first 140 amino acids are not essential for transcriptional activity. Their deletion results in a receptor with nearly wild-type levels of activity. However, deletion of the regions between amino acids 210 and 337 markedly reduces the receptor activity [<CitationRef CitationID="CR39_5">39</CitationRef>].</Para>
            <Para TextBreak="No">The first exon contains a polymorphic region that influences the interindividual variation in AR activity and prostate cancer risk. The main cause of this variability lies in a CAG nucleotide triplet repeat that begins at codon 58 and extends for an average of 21 repeats [<CitationRef CitationID="CR40_5">40</CitationRef>]. The CAG repeat region encodes a polyglutamine region, similar to those found in other transcription factors such as CREB. This region is thought to mediate AR interactions with various coregulators [<CitationRef CitationID="CR41_5">41</CitationRef>]. Indeed, as the CAG repeat length increases, the interaction of AR with its coactivator ARA24 decreases [<CitationRef CitationID="CR42_5">42</CitationRef>]. Similarly, increased CAG length seems to diminish AR interaction with members of the p160 family of coactivators [<CitationRef CitationID="CR43_5">43</CitationRef>]. CAG repeat lengths are prone to variation because DNA polymerase is subject to slippage in the regions of multiple CAG nucleotide triplets. CAG repeat length in <Emphasis Type="Italic">AR</Emphasis> ranges from 14 to 35 repeats and varies with ethnicity. Variations in the repeat length impact AR transcriptional activity, prostate growth, and prostate cancer risk [<CitationRef CitationID="CR44_5">44</CitationRef>]. Ethnic differences have been noted in CAG repeat lengths, and these differences are inversely related to prostate cancer incidence [<CitationRef CitationID="CR44_5">44</CitationRef>, <CitationRef CitationID="CR45_5">45</CitationRef>]. Shorter CAG length and increased incidence of prostate cancer has been demonstrated in diverse populations including Indian, Brazilian, and Mexican men [<CitationRef CitationID="CR46_5">46</CitationRef>–<CitationRef CitationID="CR49_5">49</CitationRef>], whereas longer CAG repeat length is associated with low prostate cancer incidence in Greenland [<CitationRef CitationID="CR50_5">50</CitationRef>].</Para>
            <Para TextBreak="No">In one instance of advanced prostate cancer, <Emphasis Type="Italic">AR</Emphasis> underwent insertional mutagenesis that interrupted the CAG repeat, effectively shortening it and increasing the AR transcriptional activity. This single example not only further underscores the importance of AR activation to prostate cancer progression but also shows the influence of CAG repeat length on AR activity [<CitationRef CitationID="CR51_5">51</CitationRef>]. Variations of CAG repeat lengths have been engineered in the <Emphasis Type="Italic">AR</Emphasis> and shown to regulate AR transcriptional activity in reporter assays [<CitationRef CitationID="CR51_5">51</CitationRef>]. Variations in CAG repeat length have also been engineered into transgenic mice that have been subjected to introduction of the human exon 1 to replace the murine exon 1. Shorter CAG repeat lengths have been shown to favor prostatic hyperplasia with advancing murine age [<CitationRef CitationID="CR52_5">52</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Alterations of the Androgen Receptor in Prostate Cancer</Heading>
            <Section2 ID="Sec3">
              <Heading>AR Gene Amplification</Heading>
              <Para TextBreak="No">It has been well established in a few studies that a common finding in patients with CRPC is the amplification of the <Emphasis Type="Italic">AR</Emphasis> gene that accounts for some instances of increased AR expression in tumor samples [<CitationRef CitationID="CR53_5">53</CitationRef>–<CitationRef CitationID="CR56_5">56</CitationRef>]. Since gene amplification requires continued selective pressure for the maintenance of the amplification, the finding is a compelling argument that AR overexpression is essential for some cases of CRPC. Interestingly, amplification of the <Emphasis Type="Italic">AR</Emphasis> gene is also an adaptive response to high-dose anti-androgen monotherapy, consistent with the in vitro findings that overexpression of a wild-type AR protein confers an agonistic response to bicalutamide [<CitationRef CitationID="CR57_5">57</CitationRef>]. <Emphasis Type="Italic">AR</Emphasis> gene amplification is associated with downstream overexpression of AR protein; however, AR overexpression is found in CRPC without <Emphasis Type="Italic">AR</Emphasis> gene amplification and thus may be achieved via alternative mechanisms [<CitationRef CitationID="CR56_5">56</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec4">
              <Heading>AR Mutations</Heading>
              <Para TextBreak="No">Androgen deprivation therapy, and particularly treatment with anti-androgens, may result in the selection of malignant cell clones with <Emphasis Type="Italic">AR</Emphasis> gene mutations [<CitationRef CitationID="CR58_5">58</CitationRef>, <CitationRef CitationID="CR59_5">59</CitationRef>]. Primary prostate cancer may have a high background of clones with AR mutations available for selection in response to androgen deprivation [<CitationRef CitationID="CR60_5">60</CitationRef>]. <Emphasis Type="Italic">AR</Emphasis> mutations found in CRPC often affect the ligand-binding domain and alter the AR response to anti-androgens and may broaden the spectrum of ligand agonists conferring greater activity to adrenal androgens [<CitationRef CitationID="CR61_5">61</CitationRef>]. A number of investigators have detected <Emphasis Type="Italic">AR</Emphasis> mutations in prostate cancer tissue [<CitationRef CitationID="CR58_5">58</CitationRef>, <CitationRef CitationID="CR62_5">62</CitationRef>–<CitationRef CitationID="CR69_5">69</CitationRef>]. Consistent with the notion of clonal selection, these <Emphasis Type="Italic">AR</Emphasis> mutations are very rare in patients with primary prostate cancer and are found with a higher frequency in patients with advanced disease [<CitationRef CitationID="CR62_5">62</CitationRef>].</Para>
              <Para TextBreak="No">The functional importance of <Emphasis Type="Italic">AR</Emphasis> mutations in CRPC is underscored by the finding that the mutations cluster in three regions of the molecule [<CitationRef CitationID="CR17_5">17</CitationRef>]. Mutations in the LBD affect the ligand-binding pocket and liberalize the spectrum of AR agonists to a wider range of steroid hormones and pharmaceutical anti-androgens [<CitationRef CitationID="CR58_5">58</CitationRef>, <CitationRef CitationID="CR61_5">61</CitationRef>, <CitationRef CitationID="CR70_5">70</CitationRef>]. <Emphasis Type="Italic">AR</Emphasis> mutations that affect the ligand-binding pocket, except for a single residue, are mutually exclusive of those that cause androgen insensitivity [<CitationRef CitationID="CR30_5">30</CitationRef>]. Mutation of methionine 740 to valine has been found in several individuals with complete or severe partial androgen insensitivity syndrome [<CitationRef CitationID="CR71_5">71</CitationRef>–<CitationRef CitationID="CR75_5">75</CitationRef>] and in prostate cancer mutated to isoleucine [<CitationRef CitationID="CR76_5">76</CitationRef>, <CitationRef CitationID="CR77_5">77</CitationRef>].</Para>
              <Para TextBreak="No">
                        <Emphasis Type="Italic">AR</Emphasis> mutations in CRPC also cluster in the region 874–910 that flanks the AF-2 domain, the region that affects the binding of p160 coactivator molecules to AR [<CitationRef CitationID="CR78_5">78</CitationRef>]. Mutations in the region of 874–900 affect the ligand-binding pocket and particularly allow anti-androgens to be recognized as agonists. Mutations that affect residues C-terminal to amino acid 880 may affect interactions with coactivators or subcellular localization of AR [<CitationRef CitationID="CR79_5">79</CitationRef>, <CitationRef CitationID="CR80_5">80</CitationRef>]. Mutations are also found in the AR hinge region that borders the DNA-binding and ligand-binding domains [<CitationRef CitationID="CR30_5">30</CitationRef>, <CitationRef CitationID="CR81_5">81</CitationRef>]. The hinge region appears to be targeted because it affects AR interactions with corepressors and thereby diminishes the efficacy of anti-androgens and may explain the sensitization of AR to ligand interactions in late-stage prostate cancer [<CitationRef CitationID="CR81_5">81</CitationRef>]. Just as steroid hormone receptors initiate transcriptional signals that have to be amplified by coactivators, the signals can be silenced by corepressors [<CitationRef CitationID="CR82_5">82</CitationRef>]. The hinge region of AR between the DNA binding and ligand-binding domains is frequently affected by mutations in prostate cancer. The mutation target region <Superscript>668</Superscript>QPIF<Superscript>671</Superscript> lies between the hinge and the ligand binding domain [<CitationRef CitationID="CR17_5">17</CitationRef>, <CitationRef CitationID="CR81_5">81</CitationRef>, <CitationRef CitationID="CR83_5">83</CitationRef>]. The four residues form a hydrophobic cleft that potentially mediates interactions with other proteins, perhaps corepressors. Deletion of the hinge region amino acids 628–646 results in significant activation of AR and marked enhancement of LXXLL-dependent ligand-dependent coactivation [<CitationRef CitationID="CR84_5">84</CitationRef>]. It is also possible that the hinge region may modulate N-terminal binding to the ligand binding domain via the FXXLF motif in the NTD. Binding between the N-terminal and ligand-binding domains can interfere with p160 coactivator binding to the AF-2 groove of the ligand-binding domain and modulate the activity of the AR signaling complex [<CitationRef CitationID="CR85_5">85</CitationRef>].</Para>
              <Para TextBreak="No">All the reported <Emphasis Type="Italic">AR</Emphasis> mutations found in prostate cancer are catalogued in the Androgen Receptor Gene Mutations Database of the Lady Davis Institute for Medical Research. The URL for The Androgen Receptor Gene Mutations Database World Wide Web Server is <ExternalRef>
                  <RefSource>http://www.mcgill.ca/androgendb/</RefSource>
                  <RefTarget Address="http://www.mcgill.ca/androgendb/" TargetType="URL"/>
                </ExternalRef>.</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Posttranslational Modification of AR</Heading>
              <Para TextBreak="No">AR activity can be enhanced by the HER family of kinases, which effect AR binding to DNA, AR stability, and interaction with the p160 coactivator TIF-2 [<CitationRef CitationID="CR86_5">86</CitationRef>, <CitationRef CitationID="CR87_5">87</CitationRef>]. AR has not been shown to be a substrate of the HER kinases but rather is a target for phosphorylation by kinases activated downstream of the HER kinases. HER2 and 3 activation by heregulin activates ACK1, which directly affects AR activity [<CitationRef CitationID="CR87_5">87</CitationRef>, <CitationRef CitationID="CR88_5">88</CitationRef>]. The inhibition of HER2 signaling decreases AR transcriptional activation [<CitationRef CitationID="CR89_5">89</CitationRef>], and ACK1 has been shown to phosphorylate AR in the NTD to enhance AR transcriptional activity [<CitationRef CitationID="CR90_5">90</CitationRef>]. HER kinase activation also results in the phosphorylation of AR at serine 578 in the DNA-binding domain. Loss The loss of serine 578 abrogates the effect of HER kinase on AR and alters the subcellular distribution of AR, demonstrating the importance of HER activity in AR regulation [<CitationRef CitationID="CR91_5">91</CitationRef>].</Para>
              <Para TextBreak="No">AR also interacts with and binds to the inner membrane tyrosine kinase SRC. In the cytoplasm, ligand-bound AR activates SRC via interaction with the AR N-terminal proline-rich domain. SRC, in turn, phosphorylates and activates the p85alpha subunit of PI3-kinase [<CitationRef CitationID="CR92_5">92</CitationRef>]. The interaction of AR and SRC also results in the phosphorylation of AR on tyrosine 534 in the NTD. SRC expression and levels of AR phosphorylated on tyrosine 534 are increased in CRPC. AR is activated by SRC phosphorylation, a modification that can facilitate the growth of prostate cancer xenografts in castrated mice [<CitationRef CitationID="CR93_5">93</CitationRef>]. Moreover, levels of SRC are increased in tissues from patients with CRPC.</Para>
              <Para TextBreak="No">AR transcripts have been shown to occur in various isoforms that result from alternative splicing events. Although these findings are to date restricted to cell lines, it has been shown that AR isoforms lacking the ligand-binding domain can be found in 22Rv1 cells and can drive transcription in a ligand-independent manner [<CitationRef CitationID="CR94_5">94</CitationRef>]. These findings are particularly important because if found in tumors, C-terminal truncated AR would be unaffected by anti-androgens and would be independent of all therapeutic measures that target ligand availability.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Ligand Availability</Heading>
            <Para TextBreak="No">CRPC has been shown to overcome androgen deprivation by altering ligand availability through androgen synthesis by malignant epithelial cells. For example, in locally recurrent prostate cancer after androgen ablation, intracellular levels of dihydrotestosterone reach physiologic concentrations, theoretically providing sufficient ligand for the local activation of AR [<CitationRef CitationID="CR95_5">95</CitationRef>]. Tissues in CRPC have also been shown to increase the expression of genes coding for enzymes that convert adrenal steroids into androgens [<CitationRef CitationID="CR96_5">96</CitationRef>]. Moreover, the malignant cells of CRPC may activate more than one enzymatic pathway to synthesize androgens and are fully capable of converting two-carbon precursors to testosterone [<CitationRef CitationID="CR97_5">97</CitationRef>]. The potential of cancer cells to increase their own supply of ligand in CRPC argues for the application of drugs that inhibit adrenal steroidogenesis and androgen synthesis. These data explain, in part, the transient clinical effects of ketoconazole [<CitationRef CitationID="CR98_5">98</CitationRef>–<CitationRef CitationID="CR100_5">100</CitationRef>] and the early phase clinical effects of abiraterone acetate, a high-affinity inhibitor of cytochrome P450 CYP17 [<CitationRef CitationID="CR101_5">101</CitationRef>, <CitationRef CitationID="CR102_5">102</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>AR Coregulators</Heading>
            <Para TextBreak="No">AR interacts with hundreds of proteins that have the potential to act as coregulators to inhibit or enhance AR transcriptional activity. Variation in the expression or structure of these coregulators can greatly alter the transcriptional activity of AR and thereby affect the development of both the normal prostate and prostatic neoplasia.</Para>
            <Para TextBreak="No">The paradigmatic family of AR coactivators is the p160 family, a group of three 160 kDa proteins SRC-1, TIF-2, and SRC-3/AIB1, with substantial sequence homology. These proteins bind to the AR at a region called TAU-5 in the NTD as well as at AF-2 in the ligand-binding domain at a groove created by the rotation of helix 12 after ligand binding [<CitationRef CitationID="CR103_5">103</CitationRef>]. P160 family coactivators amplify the transcriptional signal initiated by AR binding to DNA and in doing so recruit secondary coactivators and regulatory proteins to the transcriptional complex. Overexpression of each of the p160 proteins has been observed in prostate cancer [<CitationRef CitationID="CR104_5">104</CitationRef>].</Para>
            <Para TextBreak="No">SRC-1 and TIF-2 overexpression have been demonstrated in androgen-insensitive prostate tumors as compared with androgen-sensitive tumors and BPH specimens [<CitationRef CitationID="CR105_5">105</CitationRef>]. SRC-1 is required for normal prostate growth, and it is overexpressed in CRPC. SRC-1 has been demonstrated to potentiate AR activity even at very low hormone levels [<CitationRef CitationID="CR106_5">106</CitationRef>]. SRC-1 interacts with AR at the LBD via LXXLL motifs. In addition, SRC-1 can exert its influence independently of the C-terminal LXXLL motifs by acting at a glutamine-rich region of the AR’s C-terminal [<CitationRef CitationID="CR107_5">107</CitationRef>]. A second p160 coactivator, TIF-2, when overexpressed in prostate cancers is associated with early recurrence and a more aggressive clinical behavior [<CitationRef CitationID="CR108_5">108</CitationRef>]. High levels of AIB1/SRC-3 have been correlated with high tumor grade and stage. Overexpression of AIB1/SRC-3 has also been shown to be correlated with increased prostate cancer cell proliferation as well as decreased levels of apoptosis [<CitationRef CitationID="CR109_5">109</CitationRef>].</Para>
            <Para TextBreak="No">A number of other proteins that can potentiate AR transcription in vitro have been found to be overexpressed in prostate cancer. ARA-70 is a transcriptional coactivator that can interact with AR. ARA-70 is overexpressed in high-grade prostate cancer tissues and prostate cancer cell lines. ARA-70 interacts with AR via the N-terminal FXXLF domain and thereby can attenuate the inhibitory effects of anti-androgens [<CitationRef CitationID="CR110_5">110</CitationRef>]. Tip60 interacts with AR as well as ER and PR and is found in the nuclei of progressive and castration-resistant prostate cancer. Tip60 is upregulated as a response to androgen deprivation and accumulates in the nucleus [<CitationRef CitationID="CR111_5">111</CitationRef>]. Cdc25B is a member of the Cdc25 family of phosphatases. It activates cyclin-dependent kinases and enhances the transcriptional activity of the AR by binding directly to AR. Overexpression of Cdc25B is associated with poorly differentiated tumors as well as with high-grade disease [<CitationRef CitationID="CR112_5">112</CitationRef>]. CBP/p300 is involved in chromatin remodeling as well as the recruitment of TFIIB and TBP. A high level of expression is noted in advanced and castration-resistant prostate cancer [<CitationRef CitationID="CR113_5">113</CitationRef>]. ART27 is another AR-coactivating protein whose expression is altered in prostate cancer. It interacts with AR at the NTD. Normally found in prostate and breast tissue epithelium, ART27 expression is decreased in prostate cancer [<CitationRef CitationID="CR114_5">114</CitationRef>]. ARA55 enhances AR transactivation by binding to the C-terminal LIM domain [<CitationRef CitationID="CR115_5">115</CitationRef>]. PYK2 kinase targets ARA55 and thereby decreases interaction with AR. PYK2 expression levels decrease during prostate cancer progression thereby allowing a sustained interaction of ARA55 and AR [<CitationRef CitationID="CR116_5">116</CitationRef>].</Para>
            <Para TextBreak="No">The multifunction oncogene beta-catenin functions as an AR coactivator by interacting with the AR ligand-binding domain. The importance of beta-catenin in prostate cancer is suggested by the rare mutational activation in prostate cancer [<CitationRef CitationID="CR117_5">117</CitationRef>, <CitationRef CitationID="CR118_5">118</CitationRef>]. A more common pathway toward beta-catenin activation in prostate cancer is via methylation of <Emphasis Type="Italic">APC</Emphasis>, the gene that codes for the colon cancer suppressor that complexes with beta-catenin in the cytoplasm and mediates phosphorylation and ubiquitination to modulate the intracellular levels of beta-catenin [<CitationRef CitationID="CR119_5">119</CitationRef>–<CitationRef CitationID="CR121_5">121</CitationRef>]. In addition, GSK3beta is inactivated in advanced prostate cancer [<CitationRef CitationID="CR122_5">122</CitationRef>]. GSK3beta is a key kinase for the beta-catenin NTD that activates ubiquitination on proteasomal degradation [<CitationRef CitationID="CR123_5">123</CitationRef>]. In advanced prostate cancer, calpain cleaves beta-catenin causing an N-terminal truncation. This is, potentially, another mechanism for beta-catenin activation during late stage disease [<CitationRef CitationID="CR124_5">124</CitationRef>]. Beta-catenin activates AR transcriptional activity, translocates AR to the nucleus, and shifts the ligand response curve to the left [<CitationRef CitationID="CR125_5">125</CitationRef>–<CitationRef CitationID="CR128_5">128</CitationRef>]. Beta-catenin interacts with the AF-2 domain of AR and forms a three-way complex with AR and TIF-2 as it also binds to TIF-2 [<CitationRef CitationID="CR129_5">129</CitationRef>, <CitationRef CitationID="CR130_5">130</CitationRef>].</Para>
            <Para TextBreak="No">AR is negatively regulated by corepressor proteins that bind to AR to inhibit transcriptional activation when AR is located in the nucleus. SMRT and the closely related NcoR repress the AR by direct interaction with it. They also serve as competitors with the p160 coactivators [<CitationRef CitationID="CR131_5">131</CitationRef>]. Although some AR ligands activate binding to corepressors [<CitationRef CitationID="CR132_5">132</CitationRef>, <CitationRef CitationID="CR133_5">133</CitationRef>], anti-androgens like bicalutamide mediate disruption of coactivator binding and do not appear to work by increasing corepressor binding [<CitationRef CitationID="CR134_5">134</CitationRef>]. Alteration of corepressor expression has not been reported in prostate cancer and does not appear to be a mechanism by which AR is activated in neoplastic prostate epithelial cells.</Para>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>Summary</Heading>
            <Para TextBreak="No">Prostate cancer cells depend on AR activity at all phases of tumor progression. Androgen deprivation therapy introduces a selective pressure that results in a wide range of genetic changes and biochemical modifications to restore sufficient AR activity for cell proliferation. More successful therapy for advanced prostate cancer may require combinations of treatments for patients with metastatic castration-sensitive disease to decrease the likelihood of development of castration-resistance. The availability of new higher affinity anti-androgens, more effective inhibitors of androgen synthesis, and new kinase inhibitors have the potential to achieve prolongation of control of prostate cancer proliferation and improved survival.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_5.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_5">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Tomlins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Rhodes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Perner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>310</VolumeID>
                <IssueID>5748</IssueID>
                <FirstPage>644</FirstPage>
                <LastPage>648</LastPage>
                <Occurrence Type="PID">
                  <Handle>16254181</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFChsLjJ</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1117679</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310(5748):644–648.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_5">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Tomlins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Laxman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Varambally</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Role of the TMPRSS2-ERG gene fusion in prostate cancer</ArticleTitle>
                <JournalTitle>Neoplasia</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>177</FirstPage>
                <LastPage>188</LastPage>
                <Occurrence Type="PID">
                  <Handle>18283340</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXltleitr8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1593/neo.07822</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tomlins SA, Laxman B, Varambally S et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10(2):177–188.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_5">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Huggins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Stevens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Hodges</FamilyName>
                </BibAuthorName>
                <Year>1941</Year>
                <ArticleTitle Language="En">Studies on prostatic cancer II. The effect of castration on clinical patients with carcinoma of the prostate</ArticleTitle>
                <JournalTitle>Arch Surg</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>209</FirstPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaH3MXlt1WqtQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/archsurg.1941.01210140043004</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huggins C, Stevens RE, Hodges CL. Studies on prostatic cancer II. The effect of castration on clinical patients with carcinoma of the prostate. Arch Surg 1941; 43:209.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_5">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Huggins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CV</Initials>
                  <FamilyName>Hodges</FamilyName>
                </BibAuthorName>
                <Year>1941</Year>
                <ArticleTitle Language="En">Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>293</FirstPage>
                <LastPage>297</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaH3MXkvVCrtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huggins C, Hodges CV. Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293–297.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_5">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Sadi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Barrack</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>3057</FirstPage>
                <LastPage>3064</LastPage>
                <Occurrence Type="PID">
                  <Handle>1710537</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M3ls1Wmsg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19910615)67:12&lt;3057::AID-CNCR2820671221&gt;3.0.CO;2-S</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991; 67:3057–3064.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_5">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trachtenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <Year>1982</Year>
                <ArticleTitle Language="En">Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>127</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>466</FirstPage>
                <LastPage>471</LastPage>
                <Occurrence Type="PID">
                  <Handle>7062420</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL387ksFOnsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trachtenberg J, Walsh PC. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 1982; 127(3):466–471.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_5">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Gonor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WH</Initials>
                  <FamilyName>Lakey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WA</Initials>
                  <FamilyName>McBlain</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>131</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1196</FirstPage>
                <LastPage>1201</LastPage>
                <Occurrence Type="PID">
                  <Handle>6539385</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3hs1Gktg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gonor SE, Lakey WH, McBlain WA. Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J Urol 1984; 131(6):1196–1201.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_5">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Benson</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Gorman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>O’Brien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Holicky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Veneziale</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1599</FirstPage>
                <LastPage>1606</LastPage>
                <Occurrence Type="PID">
                  <Handle>3828960</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19870501)59:9&lt;1599::AID-CNCR2820590913&gt;3.0.CO;2-V</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Benson RC, Jr., Gorman PA, O’Brien PC, Holicky EL, Veneziale CM. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 1987; 59(9):1599–1606.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_5">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Rennie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Bruchovsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Goldenberg</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">Relationship of androgen receptors to the growth and regression of the prostate</ArticleTitle>
                <JournalTitle>Am J Clin Oncol</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>S13</FirstPage>
                <Occurrence Type="PID">
                  <Handle>3071950</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000421-198801102-00004</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rennie PS, Bruchovsky N, Goldenberg SL. Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 1988; 11:S13.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_5">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Castellanos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Galan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Calvo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <Year>1982</Year>
                <ArticleTitle Language="En">Predicting response of prostatic carcinoma to endocrine therapy</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>1</VolumeID>
                <IssueID>8269</IssueID>
                <FirstPage>448</FirstPage>
                <Occurrence Type="PID">
                  <Handle>6121112</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL387kslelsg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(82)91645-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Castellanos JM, Galan A, Calvo MA, Schwartz S. Predicting response of prostatic carcinoma to endocrine therapy. Lancet 1982; 1(8269):448.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_5">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CD</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Welsbie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Tran</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Molecular determinants of resistance to antiandrogen therapy</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>33</FirstPage>
                <LastPage>39</LastPage>
                <Occurrence Type="PID">
                  <Handle>14702632</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm972</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlsFGj</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10(1):33–39.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_5">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Roy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Lavrovsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Song</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Regulation of androgen action</ArticleTitle>
                <JournalTitle>Vitam Horm</JournalTitle>
                <VolumeID>55</VolumeID>
                <FirstPage>309</FirstPage>
                <LastPage>352</LastPage>
                <Occurrence Type="PID">
                  <Handle>9949684</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmsVGk</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0083-6729(08)60938-3</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Roy AK, Lavrovsky Y, Song CS et al. Regulation of androgen action. Vitam Horm 1999; 55:309–352.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_5">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Androgen receptor mutations in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Treat Res</JournalTitle>
                <VolumeID>87</VolumeID>
                <FirstPage>285</FirstPage>
                <LastPage>302</LastPage>
                <Occurrence Type="PID">
                  <Handle>8886458</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXitFWntLs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/978-1-4613-1267-3_12</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gelmann EP. Androgen receptor mutations in prostate cancer. Cancer Treat Res 1996; 87:285–302.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_5">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Saltzman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Androgen receptor: an overview</ArticleTitle>
                <JournalTitle>Crit Rev Eukaryot Gene Expr</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>97</FirstPage>
                <LastPage>125</LastPage>
                <Occurrence Type="PID">
                  <Handle>8845584</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXpsVCjs70%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1615/CritRevEukarGeneExpr.v5.i2.10</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chang C, Saltzman A, Yeh S et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 1995; 5(2):97–125.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_5">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lindzey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Kumar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Grossman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Young</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Molecular mechanisms of androgen action</ArticleTitle>
                <JournalTitle>Vitam Horm</JournalTitle>
                <VolumeID>49</VolumeID>
                <FirstPage>383</FirstPage>
                <LastPage>432</LastPage>
                <Occurrence Type="PID">
                  <Handle>7810074</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXjsVagsL0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0083-6729(08)61151-6</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam Horm 1994; 49:383–432.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_5">
              <CitationNumber>16.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Quigley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bellis</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KB</Initials>
                  <FamilyName>Marschke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>el Awady</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Androgen receptor defects: historical, clinical, and molecular perspectives</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>271</FirstPage>
                <LastPage>321</LastPage>
                <Occurrence Type="PID">
                  <Handle>7671849</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmslCqtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Quigley CA, De Bellis A, Marschke KB, el Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16(3):271–321.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_5">
              <CitationNumber>17.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Buchanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VR</Initials>
                  <FamilyName>Marshall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Tilley</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Collocation of androgen receptor gene mutations in prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1273</FirstPage>
                <LastPage>1281</LastPage>
                <Occurrence Type="PID">
                  <Handle>11350894</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktlelsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001; 7(5):1273–1281.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_5">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OA</Initials>
                  <FamilyName>Janne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Moilanen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Poukka</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Androgen-receptor-interacting nuclear proteins</ArticleTitle>
                <JournalTitle>Biochem Soc Trans</JournalTitle>
                <VolumeID>28</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>401</FirstPage>
                <LastPage>405</LastPage>
                <Occurrence Type="PID">
                  <Handle>10961928</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmsVehsr4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1042/0300-5127:0280401</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Janne OA, Moilanen AM, Poukka H et al. Androgen-receptor-interacting nuclear proteins. Biochem Soc Trans 2000; 28(4):401–405.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_5">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Ho</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Clinical review 134: the endocrinology of prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>86</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3467</FirstPage>
                <LastPage>3477</LastPage>
                <Occurrence Type="PID">
                  <Handle>11502765</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlvFeksb8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.86.8.3467</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Ho SM. Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab 2001; 86(8):3467–3477.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_5">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Bentel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Tilley</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Androgen receptors in prostate cancer</ArticleTitle>
                <JournalTitle>J Endocrinol</JournalTitle>
                <VolumeID>151</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>1</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>8943763</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s%2FpvFWrtA%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/joe.0.1510001</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996; 151(1):1–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_5">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Lubahn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Joseph</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Sullivan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HF</Initials>
                  <FamilyName>Willard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">Cloning of human androgen receptor complementary DNA and localization to the X chromosome</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>240</VolumeID>
                <IssueID>4850</IssueID>
                <FirstPage>327</FirstPage>
                <LastPage>330</LastPage>
                <Occurrence Type="PID">
                  <Handle>3353727</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1cXhvF2nsrs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.3353727</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988; 240(4850):327–330.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_5">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Goss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Lubahn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism</ArticleTitle>
                <JournalTitle>Am J Hum Genet</JournalTitle>
                <VolumeID>44</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>264</FirstPage>
                <LastPage>269</LastPage>
                <Occurrence Type="PID">
                  <Handle>2563196</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXhs1Ogt70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brown CJ, Goss SJ, Lubahn DB et al. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet 1989; 44(2):264–269.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_5">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AB</Initials>
                  <FamilyName>Wisniewski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Migeon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HF</Initials>
                  <FamilyName>Meyer-Bahlburg</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2664</FirstPage>
                <LastPage>2669</LastPage>
                <Occurrence Type="PID">
                  <Handle>10946863</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXnslaiu78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.85.8.2664</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF et al. Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab 2000; 85(8):2664–2669.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_5">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Lubahn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TR</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Simental</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>86</VolumeID>
                <IssueID>23</IssueID>
                <FirstPage>9534</FirstPage>
                <LastPage>9538</LastPage>
                <Occurrence Type="PID">
                  <Handle>2594783</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXktFyltL8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.86.23.9534</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lubahn DB, Brown TR, Simental JA et al. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci U S A 1989; 86(23):9534–9538.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_5">
              <CitationNumber>25.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Kuiper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Faber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HC</Initials>
                  <FamilyName>Rooij</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Structural organization of the human androgen receptor gene</ArticleTitle>
                <JournalTitle>J Mol Endocrinol</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>R1</FirstPage>
                <LastPage>R4</LastPage>
                <Occurrence Type="PID">
                  <Handle>2546571</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXktFyksr4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/jme.0.002R001</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kuiper GG, Faber PW, van Rooij HC et al. Structural organization of the human androgen receptor gene. J Mol Endocrinol 1989; 2(3):R1–R4.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_5">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Faber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HC</Initials>
                  <FamilyName>Rooij</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Schipper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AO</Initials>
                  <FamilyName>Brinkmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trapman</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>268</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>9296</FirstPage>
                <LastPage>9301</LastPage>
                <Occurrence Type="PID">
                  <Handle>8486625</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXktVantr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Faber PW, van Rooij HC, Schipper HJ, Brinkmann AO, Trapman J. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem 1993; 268(13):9296–9301.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_5">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Tilley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Marcelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>McPhaul</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Characterization and expression of a cDNA encoding the human androgen receptor</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>86</VolumeID>
                <FirstPage>327</FirstPage>
                <LastPage>331</LastPage>
                <Occurrence Type="PID">
                  <Handle>2911578</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXlt1Oqsbo%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.86.1.327</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 1989; 86:327–331.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_5">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Spencer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Watson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Lubahn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">The androgen receptor gene is located on a highly conserved region of the X chromosomes of marsupial and monotreme as well as eutherian mammals</ArticleTitle>
                <JournalTitle>J Hered</JournalTitle>
                <VolumeID>82</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>134</FirstPage>
                <LastPage>139</LastPage>
                <Occurrence Type="PID">
                  <Handle>2013687</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XhsVGitLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Spencer JA, Watson JM, Lubahn DB et al. The androgen receptor gene is located on a highly conserved region of the X chromosomes of marsupial and monotreme as well as eutherian mammals. J Hered 1991; 82(2):134–139.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_5">
              <CitationNumber>29.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Choong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Kemppainen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Evolution of the primate androgen receptor: a structural basis for disease</ArticleTitle>
                <JournalTitle>J Mol Evol</JournalTitle>
                <VolumeID>47</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>334</FirstPage>
                <LastPage>342</LastPage>
                <Occurrence Type="PID">
                  <Handle>9732460</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmt1anurs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/PL00006391</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Choong CS, Kemppainen JA, Wilson EM. Evolution of the primate androgen receptor: a structural basis for disease. J Mol Evol 1998; 47(3):334–342.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_5">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Matias</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Donner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Coelho</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>275</VolumeID>
                <IssueID>34</IssueID>
                <FirstPage>26164</FirstPage>
                <LastPage>26171</LastPage>
                <Occurrence Type="PID">
                  <Handle>10840043</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmt1OksLk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M004571200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Matias PM, Donner P, Coelho R et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275(34):26164–26171.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_5">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Sack</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KF</Initials>
                  <FamilyName>Kish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>98</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>4904</FirstPage>
                <LastPage>4909</LastPage>
                <Occurrence Type="PID">
                  <Handle>11320241</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjt1Ogtbs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.081565498</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sack JS, Kish KF, Wang C et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 2001; 98(9):4904–4909.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_5">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Shiau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Barstad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Loria</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>95</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>927</FirstPage>
                <LastPage>937</LastPage>
                <Occurrence Type="PID">
                  <Handle>9875847</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjslyltQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0092-8674(00)81717-1</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shiau AK, Barstad D, Loria PM et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7):927–937.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_5">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Brzozowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Pike</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Dauter</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Molecular basis of agonism and antagonism in the oestrogen receptor</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>389</VolumeID>
                <IssueID>6652</IssueID>
                <FirstPage>753</FirstPage>
                <LastPage>758</LastPage>
                <Occurrence Type="PID">
                  <Handle>9338790</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmvVSnt74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/39645</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brzozowski AM, Pike AC, Dauter Z et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652):753–758.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_5">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Tanenbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Williams</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Sigler</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>95</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>5998</FirstPage>
                <LastPage>6003</LastPage>
                <Occurrence Type="PID">
                  <Handle>9600906</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjtlKhurw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.95.11.5998</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains. Proc Natl Acad Sci U S A 1998; 95(11):5998–6003.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_5">
              <CitationNumber>35.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Nolte</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GB</Initials>
                  <FamilyName>Wisely</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Westin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>395</VolumeID>
                <IssueID>6698</IssueID>
                <FirstPage>137</FirstPage>
                <LastPage>143</LastPage>
                <Occurrence Type="PID">
                  <Handle>9744270</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmtVekt7k%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/25931</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nolte RT, Wisely GB, Westin S et al. Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma. Nature 1998; 395(6698):137–143.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_5">
              <CitationNumber>36.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CI</Initials>
                  <FamilyName>Wong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZX</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>268</VolumeID>
                <IssueID>25</IssueID>
                <FirstPage>19004</FirstPage>
                <LastPage>19012</LastPage>
                <Occurrence Type="PID">
                  <Handle>8360187</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXlslCns7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wong CI, Zhou ZX, Sar M, Wilson EM. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem 1993; 268(25):19004–19012.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_5">
              <CitationNumber>37.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Langley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZX</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>270</VolumeID>
                <IssueID>50</IssueID>
                <FirstPage>29983</FirstPage>
                <LastPage>29990</LastPage>
                <Occurrence Type="PID">
                  <Handle>8530400</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXhtVSitbnN</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.270.50.29983</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Langley E, Zhou ZX, Wilson EM. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 1995; 270(50):29983–29990.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_5">
              <CitationNumber>38.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Liao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Redox-dependent DNA binding of the purified androgen receptor: evidence for disulfide-linked androgen receptor dimers</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>38</VolumeID>
                <IssueID>30</IssueID>
                <FirstPage>9718</FirstPage>
                <LastPage>9727</LastPage>
                <Occurrence Type="PID">
                  <Handle>10423251</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXktVagsrg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/bi990589i</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liao M, Zhou Z, Wilson EM. Redox-dependent DNA binding of the purified androgen receptor: evidence for disulfide-linked androgen receptor dimers. Biochemistry 1999; 38(30):9718–9727.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_5">
              <CitationNumber>39.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Simental</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Lane</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Transcriptional activation and nuclear targeting signals of the human androgen receptor</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>266</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>510</FirstPage>
                <LastPage>518</LastPage>
                <Occurrence Type="PID">
                  <Handle>1985913</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXhtFGhtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991; 266(1):510–518.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_5">
              <CitationNumber>40.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Spada</FamilyName>
                  <Particle>La</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Lubahn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AE</Initials>
                  <FamilyName>Harding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Fischbeck</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>352</VolumeID>
                <IssueID>6330</IssueID>
                <FirstPage>77</FirstPage>
                <LastPage>79</LastPage>
                <Occurrence Type="PID">
                  <Handle>2062380</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/352077a0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352(6330):77–79.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_5">
              <CitationNumber>41.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Heinlein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen receptor in prostate cancer</ArticleTitle>
                <JournalTitle>Endocr Rev</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>276</FirstPage>
                <LastPage>308</LastPage>
                <Occurrence Type="PID">
                  <Handle>15082523</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXktFSqtLY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/er.2002-0032</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25(2):276–308.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_5">
              <CitationNumber>42.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Hsiao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Nakao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">The linkage of Kennedy’s neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>274</VolumeID>
                <IssueID>29</IssueID>
                <FirstPage>20229</FirstPage>
                <LastPage>20234</LastPage>
                <Occurrence Type="PID">
                  <Handle>10400640</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXks1Ojs70%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.274.29.20229</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsiao PW, Lin DL, Nakao R, Chang C. The linkage of Kennedy’s neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem 1999; 274(29):20229–20234.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_5">
              <CitationNumber>43.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Irvine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Ma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Stallcup</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Coetzee</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length</ArticleTitle>
                <JournalTitle>Hum Mol Genet</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>267</FirstPage>
                <LastPage>274</LastPage>
                <Occurrence Type="PID">
                  <Handle>10607837</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXhtVaksLs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/hmg/9.2.267</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000; 9(2):267–274.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_5">
              <CitationNumber>44.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Q</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Eastham</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>53</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>378</FirstPage>
                <LastPage>380</LastPage>
                <Occurrence Type="PID">
                  <Handle>9933058</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M7ivFygug%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(98)00481-6</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 1999; 53(2):378–380.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_5">
              <CitationNumber>45.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Andersson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Varenhorst</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Soderkvist</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>42</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>2833</FirstPage>
                <LastPage>2837</LastPage>
                <Occurrence Type="PID">
                  <Handle>17010601</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFSrtb3E</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ejca.2006.06.030</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Andersson P, Varenhorst E, Soderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer 2006; 42(16):2833–2837.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_5">
              <CitationNumber>46.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NB</Initials>
                  <FamilyName>Silva</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Koff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Biolchi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population</ArticleTitle>
                <JournalTitle>Cancer Invest</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>74</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1080/07357900701638251</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXisFOltw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Silva NB, Koff WJ, Biolchi V et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008; 26(1):74–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_5">
              <CitationNumber>47.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RD</Initials>
                  <FamilyName>Mittal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Mishra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Mandhani</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in Indian population</ArticleTitle>
                <JournalTitle>Asian Pac J Cancer Prev</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>275</FirstPage>
                <LastPage>278</LastPage>
                <Occurrence Type="PID">
                  <Handle>17696745</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mittal RD, Mishra D, Mandhani AK. Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in Indian population. Asian Pac J Cancer Prev 2007; 8(2):275–278.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_5">
              <CitationNumber>48.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Patino-Garcia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Arroyo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Rangel-Villalobos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population</ArticleTitle>
                <JournalTitle>Rev Invest Clin</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>25</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>17569297</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmt1Gjtrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Patino-Garcia B, Arroyo C, Rangel-Villalobos H et al. Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population. Rev Invest Clin 2007; 59(1):25–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_5">
              <CitationNumber>49.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Krishnaswamy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kumarasamy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Venkatesan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Shroff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VR</Initials>
                  <FamilyName>Jayanth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Paul</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer</ArticleTitle>
                <JournalTitle>J Hum Genet</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>254</FirstPage>
                <LastPage>257</LastPage>
                <Occurrence Type="PID">
                  <Handle>16437189</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xis1Okt78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10038-005-0346-5</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Krishnaswamy V, Kumarasamy T, Venkatesan V, Shroff S, Jayanth VR, Paul SF. South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer. J Hum Genet 2006; 51(3):254–257.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_5">
              <CitationNumber>50.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Giwercman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Giwercman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HS</Initials>
                  <FamilyName>Pedersen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians</ArticleTitle>
                <JournalTitle>Int J Androl</JournalTitle>
                <VolumeID>31</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>25</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>17376218</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXivVOls7c%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1365-2605.2007.00750.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Giwercman C, Giwercman A, Pedersen HS et al. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians. Int J Androl 2008; 31(1):25–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_5">
              <CitationNumber>51.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Buchanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Cheong</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Structural and functional consequences of glutamine tract variation in the androgen receptor</ArticleTitle>
                <JournalTitle>Hum Mol Genet</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>1677</FirstPage>
                <LastPage>1692</LastPage>
                <Occurrence Type="PID">
                  <Handle>15198988</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlvFGqsb0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/hmg/ddh181</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Buchanan G, Yang M, Cheong A et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 2004; 13(16):1677–1692.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_5">
              <CitationNumber>52.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Robins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Albertelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OA</Initials>
                  <FamilyName>O’Mahony</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Androgen receptor variants and prostate cancer in humanized AR mice</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>108</VolumeID>
                <IssueID>3–5</IssueID>
                <FirstPage>230</FirstPage>
                <LastPage>236</LastPage>
                <Occurrence Type="PID">
                  <Handle>17936615</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhsFyntbo%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.jsbmb.2007.09.002</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Robins DM, Albertelli MA, O’Mahony OA. Androgen receptor variants and prostate cancer in humanized AR mice. J Steroid Biochem Mol Biol 2008; 108(3–5):230–236.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_5">
              <CitationNumber>53.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Visakorpi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hyytinen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Koivisto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">In vivo amplification of the androgen receptor gene and progression of human prostate cancer</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>401</FirstPage>
                <LastPage>406</LastPage>
                <Occurrence Type="PID">
                  <Handle>7795646</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXkvV2jurc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng0495-401</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9(4):401–406.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_5">
              <CitationNumber>54.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Koivisto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Visakorpi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OP</Initials>
                  <FamilyName>Kallioniemi</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer</ArticleTitle>
                <JournalTitle>Scand J Clin Lab Invest Suppl</JournalTitle>
                <VolumeID>226</VolumeID>
                <FirstPage>57</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>8981668</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s7js1Wgsw%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1080/00365519609168299</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Koivisto P, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 1996; 226:57–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_5">
              <CitationNumber>55.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Miyoshi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Uemura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Fujinami</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>43</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>225</FirstPage>
                <LastPage>232</LastPage>
                <Occurrence Type="PID">
                  <Handle>10797498</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjs1Wrsrs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(20000515)43:3&lt;225::AID-PROS9&gt;3.0.CO;2-7</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miyoshi Y, Uemura H, Fujinami K et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000; 43(3):225–232.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_5">
              <CitationNumber>56.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Linja</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Savinainen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OR</Initials>
                  <FamilyName>Saramaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Tammela</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Visakorpi</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Amplification and overexpression of androgen receptor gene in hormone- refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>3550</FirstPage>
                <LastPage>3555</LastPage>
                <Occurrence Type="PID">
                  <Handle>11325816</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjsFCgt7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone- refractory prostate cancer. Cancer Res 2001; 61(9):3550–3555.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_5">
              <CitationNumber>57.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Palmberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Koivisto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hyytinen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>31</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>216</FirstPage>
                <LastPage>219</LastPage>
                <Occurrence Type="PID">
                  <Handle>9076469</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s3jtFSksQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Palmberg C, Koivisto P, Hyytinen E et al. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997; 31(2):216–219.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_5">
              <CitationNumber>58.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TD</Initials>
                  <FamilyName>Shuster</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>332</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>1393</FirstPage>
                <LastPage>1398</LastPage>
                <Occurrence Type="PID">
                  <Handle>7723794</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmvVWnsbs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199505253322101</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332(21):1393–1398.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_5">
              <CitationNumber>59.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YJ</Initials>
                  <FamilyName>Ko</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2511</FirstPage>
                <LastPage>2515</LastPage>
                <Occurrence Type="PID">
                  <Handle>10363963</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjs1yms7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11):2511–2515.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_5">
              <CitationNumber>60.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Tilley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Buchanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TE</Initials>
                  <FamilyName>Hickey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Bentel</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>277</FirstPage>
                <LastPage>285</LastPage>
                <Occurrence Type="PID">
                  <Handle>9816170</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xhs1SktL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2(2):277–285.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_5">
              <CitationNumber>61.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Tan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Sharief</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KG</Initials>
                  <FamilyName>Hamil</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>450</FirstPage>
                <LastPage>459</LastPage>
                <Occurrence Type="PID">
                  <Handle>9092797</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXitF2nu78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.11.4.450</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tan J, Sharief Y, Hamil KG et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997; 11(4):450–459.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_5">
              <CitationNumber>62.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Marcelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ittmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mariani</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Androgen receptor mutations in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>944</FirstPage>
                <LastPage>949</LastPage>
                <Occurrence Type="PID">
                  <Handle>10706109</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXhs1Shs78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60(4):944–949.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_5">
              <CitationNumber>63.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Barrack</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Androgen receptor mutations in prostate cancer</ArticleTitle>
                <JournalTitle>Mt Sinai J Med</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>5–6</IssueID>
                <FirstPage>403</FirstPage>
                <LastPage>412</LastPage>
                <Occurrence Type="PID">
                  <Handle>8898547</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s%2FlsVWlug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Barrack ER. Androgen receptor mutations in prostate cancer. Mt Sinai J Med 1996; 63(5–6):403–412.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_5">
              <CitationNumber>64.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hittmair</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy</ArticleTitle>
                <JournalTitle>Drugs Aging</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>50</FirstPage>
                <LastPage>58</LastPage>
                <Occurrence Type="PID">
                  <Handle>9111707</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s3msFynug%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2165/00002512-199710010-00005</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Culig Z, Hobisch A, Hittmair A et al. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 1997; 10(1):50–58.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_5">
              <CitationNumber>65.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Uchida</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">[Androgen receptor gene mutations in prostate cancer]</ArticleTitle>
                <JournalTitle>Nippon Hinyokika Gakkai Zasshi</JournalTitle>
                <VolumeID>88</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>550</FirstPage>
                <LastPage>556</LastPage>
                <Occurrence Type="PID">
                  <Handle>9184448</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2szislymtA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.5980/jpnjurol1989.88.550</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Wang C, Uchida T. [Androgen receptor gene mutations in prostate cancer]. Nippon Hinyokika Gakkai Zasshi 1997; 88(5):550–556.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_5">
              <CitationNumber>66.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Watabe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Masai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Seino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Shimazaki</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Androgen receptor gene mutations in human prostate cancer</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>46</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>759</FirstPage>
                <LastPage>765</LastPage>
                <Occurrence Type="PID">
                  <Handle>8274409</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhtVels74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0960-0760(93)90316-O</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46(6):759–765.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_5">
              <CitationNumber>67.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Newmark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DO</Initials>
                  <FamilyName>Hardy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DC</Initials>
                  <FamilyName>Tonb</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Androgen receptor gene mutations in human prostate cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>6319</FirstPage>
                <LastPage>6323</LastPage>
                <Occurrence Type="PID">
                  <Handle>1631125</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xlt12jtLw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.89.14.6319</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Newmark JR, Hardy DO, Tonb DC et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 1992; 89(14):6319–6323.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_5">
              <CitationNumber>68.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Wallen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Linja</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kaartinen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schleutker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Visakorpi</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Androgen receptor gene mutations in hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Pathol</JournalTitle>
                <VolumeID>189</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>559</FirstPage>
                <LastPage>563</LastPage>
                <Occurrence Type="PID">
                  <Handle>10629558</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXltlSrug%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1096-9896(199912)189:4&lt;559::AID-PATH471&gt;3.0.CO;2-Y</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999; 189(4):559–563.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_5">
              <CitationNumber>69.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Castagnaro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Yandell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Dockhorn-Dworniczak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Wolfe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Poremba</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">[Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer]</ArticleTitle>
                <JournalTitle>Verh Dtsch Ges Pathol</JournalTitle>
                <VolumeID>77</VolumeID>
                <FirstPage>119</FirstPage>
                <LastPage>123</LastPage>
                <Occurrence Type="PID">
                  <Handle>7511268</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXisVWgu78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, Wolfe HJ, Poremba C. [Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer]. Verh Dtsch Ges Pathol 1993; 77:119–123.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_5">
              <CitationNumber>70.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Veldscholte</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Voorhorst-Ogink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Bolt-de Vries</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HC</Initials>
                  <FamilyName>van Rooij</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trapman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Mulder</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids</ArticleTitle>
                <JournalTitle>Biochim Biophys Acta</JournalTitle>
                <VolumeID>1052</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>187</FirstPage>
                <LastPage>194</LastPage>
                <Occurrence Type="PID">
                  <Handle>2322591</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXitleitb0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0167-4889(90)90075-O</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooij HC, Trapman J, Mulder E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1990; 1052(1):187–194.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_5">
              <CitationNumber>71.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>De</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Quigley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NF</Initials>
                  <FamilyName>Cariello</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1909</FirstPage>
                <LastPage>1920</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.6.11.1909</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>De BA, Quigley CA, Cariello NF et al. Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique. Mol Endocrinol 1992; 6(11):1909–1920.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_5">
              <CitationNumber>72.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Jakubiczka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Werder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Wieacker</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Point mutation in the steroid-binding domain of the androgen receptor gene in a family with complete androgen insensitivity syndrome (CAIS)</ArticleTitle>
                <JournalTitle>Hum Genet</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>311</FirstPage>
                <LastPage>312</LastPage>
                <Occurrence Type="PID">
                  <Handle>1487249</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXkt1Grs7g%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00220088</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jakubiczka S, Werder EA, Wieacker P. Point mutation in the steroid-binding domain of the androgen receptor gene in a family with complete androgen insensitivity syndrome (CAIS). Hum Genet 1992; 90(3):311–312.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_5">
              <CitationNumber>73.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Ahmed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Dovey</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>658</FirstPage>
                <LastPage>665</LastPage>
                <Occurrence Type="PID">
                  <Handle>10690872</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXhtlyhurg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.85.2.658</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ahmed SF, Cheng A, Dovey L et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85(2):658–665.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_5">
              <CitationNumber>74.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>YH</Initials>
                  <FamilyName>Van</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SF</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Luo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Hwang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>Lo</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Novel point mutations in complete androgen insensitivity syndrome with incomplete mullerian regression: two Taiwanese patients</ArticleTitle>
                <JournalTitle>Eur J Pediatr</JournalTitle>
                <VolumeID>162</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>781</FirstPage>
                <LastPage>784</LastPage>
                <Occurrence Type="PID">
                  <Handle>13680382</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXosF2msbg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00431-003-1301-0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Van YH, Lin JL, Huang SF, Luo CC, Hwang CS, Lo FS. Novel point mutations in complete androgen insensitivity syndrome with incomplete mullerian regression: two Taiwanese patients. Eur J Pediatr 2003; 162(11):781–784.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_5">
              <CitationNumber>75.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Bouvattier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Carel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Lecointre</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Postnatal changes of T, LH, and FSH in 46, XY infants with mutations in the AR gene</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>87</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>29</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>11788616</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XntVyhsg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.87.1.29</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bouvattier C, Carel JC, Lecointre C et al. Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene. J Clin Endocrinol Metab 2002; 87(1):29–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_5">
              <CitationNumber>76.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Takahashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Furusato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Allsbrook</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>55</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1621</FirstPage>
                <LastPage>1624</LastPage>
                <Occurrence Type="PID">
                  <Handle>7712463</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXltVSlsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Takahashi H, Furusato M, Allsbrook WC, Jr. et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995; 55(8):1621–1624.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_5">
              <CitationNumber>77.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Haapala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Hyytinen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Roiha</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide</ArticleTitle>
                <JournalTitle>Lab Invest</JournalTitle>
                <VolumeID>81</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>1647</FirstPage>
                <LastPage>1651</LastPage>
                <Occurrence Type="PID">
                  <Handle>11742035</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xks1agtw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/labinvest.3780378</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Haapala K, Hyytinen ER, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81(12):1647–1651.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_5">
              <CitationNumber>78.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Johnson</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2892</FirstPage>
                <LastPage>2898</LastPage>
                <Occurrence Type="PID">
                  <Handle>11306464</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXivFGru7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61(7):2892–2898.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_5">
              <CitationNumber>79.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>395</FirstPage>
                <LastPage>406</LastPage>
                <Occurrence Type="PID">
                  <Handle>15617028</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltV2qs78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20191</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen G, Wang X, Zhang S et al. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 2005; 63(4):395–406.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_5">
              <CitationNumber>80.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Jagla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Feve</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kessler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>148</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>4334</FirstPage>
                <LastPage>4343</LastPage>
                <Occurrence Type="PID">
                  <Handle>17540719</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXpslCntbk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/en.2007-0446</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jagla M, Feve M, Kessler P et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007; 148(9):4334–4343</BibUnstructured>
            </Citation>
            <Citation ID="CR81_5">
              <CitationNumber>81.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Buchanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>46</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>11145738</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktVKnuw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.15.1.46</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Buchanan G, Yang M, Harris JM et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 2001; 15(1):46–56.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_5">
              <CitationNumber>82.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Jackson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Bain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Richer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Takimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Tung</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Nuclear receptor coactivators and corepressors</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1167</FirstPage>
                <LastPage>1177</LastPage>
                <Occurrence Type="PID">
                  <Handle>9121485</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmtF2ht7c%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.10.10.1167</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10(10):1167–1177.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_5">
              <CitationNumber>83.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>DeMayo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Finegold</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Prostate cancer in a transgenic mouse</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>92</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3439</FirstPage>
                <LastPage>3443</LastPage>
                <Occurrence Type="PID">
                  <Handle>7724580</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXltFSmsr4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.92.8.3439</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Greenberg NM, DeMayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92(8):3439–3443.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_5">
              <CitationNumber>84.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Q</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Yong</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>276</VolumeID>
                <FirstPage>7493</FirstPage>
                <LastPage>7499</LastPage>
                <Occurrence Type="PID">
                  <Handle>11102454</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXislKmsbg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M009916200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang Q, Lu J, Yong EL. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 2001; 276:7493–7499.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_5">
              <CitationNumber>85.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NT</Initials>
                  <FamilyName>Bowen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Minges</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>276</VolumeID>
                <IssueID>45</IssueID>
                <FirstPage>42293</FirstPage>
                <LastPage>42301</LastPage>
                <Occurrence Type="PID">
                  <Handle>11551963</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXosVGms7w%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M107492200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>He B, Bowen NT, Minges JT, Wilson EM. Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 2001; 276(45):42293–42301.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_5">
              <CitationNumber>86.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Fei</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Ponguta</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>7119</FirstPage>
                <LastPage>7130</LastPage>
                <Occurrence Type="PID">
                  <Handle>14662770</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXht1CksLg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M307649200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gregory CW, Fei X, Ponguta LA et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004; 279(8):7119–7130.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_5">
              <CitationNumber>87.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IK</Initials>
                  <FamilyName>Mellinghoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Vivanco</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kwon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Tran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Wongvipat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Sawyers</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>517</FirstPage>
                <LastPage>527</LastPage>
                <Occurrence Type="PID">
                  <Handle>15542435</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVGlurjI</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ccr.2004.09.031</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004; 6(5):517–527.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_5">
              <CitationNumber>88.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YE</Initials>
                  <FamilyName>Whang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>McCall</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1704</FirstPage>
                <LastPage>1712</LastPage>
                <Occurrence Type="PID">
                  <Handle>15755991</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXitVKrsr8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-1158</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gregory CW, Whang YE, McCall W et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005; 11(5):1704–1712.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_5">
              <CitationNumber>89.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Majumder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>McCall</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3404</FirstPage>
                <LastPage>3409</LastPage>
                <Occurrence Type="PID">
                  <Handle>15833875</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjt1yrsb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liu Y, Majumder S, McCall W et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005; 65(8):3404–3409.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_5">
              <CitationNumber>90.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NP</Initials>
                  <FamilyName>Mahajan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Majumder</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>104</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>8438</FirstPage>
                <LastPage>8443</LastPage>
                <Occurrence Type="PID">
                  <Handle>17494760</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmtVCht7s%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0700420104</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mahajan NP, Liu Y, Majumder S et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A 2007; 104(20):8438–8443.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_5">
              <CitationNumber>91.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Ponguta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Site specific androgen receptor serine phosphorylation linked to epidermal growth factor dependent growth of castration-recurrent prostate cancer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>283</VolumeID>
                <IssueID>30</IssueID>
                <FirstPage>20989</FirstPage>
                <LastPage>21001</LastPage>
                <Occurrence Type="PID">
                  <Handle>18511414</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXoslWrt78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M802392200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ponguta LA, Gregory CW, French FS, Wilson EM. Site specific androgen receptor serine phosphorylation linked to epidermal growth factor dependent growth of castration-recurrent prostate cancer. J Biol Chem 2008; 283(30):20989–21001.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_5">
              <CitationNumber>92.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RI</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>278</VolumeID>
                <IssueID>44</IssueID>
                <FirstPage>42992</FirstPage>
                <LastPage>43000</LastPage>
                <Occurrence Type="PID">
                  <Handle>12933816</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXosFSktL4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M306295200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sun M, Yang L, Feldman RI et al. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 2003; 278(44):42992–43000.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_5">
              <CitationNumber>93.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Guo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Jiang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Regulation of androgen receptor activity by tyrosine phosphorylation</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>309</FirstPage>
                <LastPage>319</LastPage>
                <Occurrence Type="PID">
                  <Handle>17045208</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFCgsbjI</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ccr.2006.08.021</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Guo Z, Dai B, Jiang T et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006; 10(4):309–319.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_5">
              <CitationNumber>94.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Dehm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Heemers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>5469</FirstPage>
                <LastPage>5477</LastPage>
                <Occurrence Type="PID">
                  <Handle>18593950</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnvFyjurY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-08-0594</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68(13):5469–5477.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_5">
              <CitationNumber>95.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Ford</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">The androgen axis in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>440</FirstPage>
                <LastPage>448</LastPage>
                <Occurrence Type="PID">
                  <Handle>14760063</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXovVGktA%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-1146-03</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mohler JL, Gregory CW, Ford OH, III et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440–448.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_5">
              <CitationNumber>96.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Stanbrough</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>2815</FirstPage>
                <LastPage>2825</LastPage>
                <Occurrence Type="PID">
                  <Handle>16510604</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhvV2gt7Y%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-05-4000</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66(5):2815–2825.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_5">
              <CitationNumber>97.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Locke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Guns</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Lubik</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>6407</FirstPage>
                <LastPage>6415</LastPage>
                <Occurrence Type="PID">
                  <Handle>18676866</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXpt1Wjt7o%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-5997</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68(15):6407–6415.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_5">
              <CitationNumber>98.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trachtenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Halpern</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Pont</FamilyName>
                </BibAuthorName>
                <Year>1983</Year>
                <ArticleTitle Language="En">Ketoconazole: a novel and rapid treatment for advanced prostatic cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>130</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>152</FirstPage>
                <LastPage>153</LastPage>
                <Occurrence Type="PID">
                  <Handle>6306286</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL3s3ktF2lsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 1983; 130(1):152–153.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_5">
              <CitationNumber>99.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trachtenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Pont</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Ketoconazole therapy for advanced prostate cancer</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>8400</IssueID>
                <FirstPage>433</FirstPage>
                <LastPage>435</LastPage>
                <Occurrence Type="PID">
                  <Handle>6147504</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3psVaqsw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(84)92909-X</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet 1984; 2(8400):433–435.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_5">
              <CitationNumber>100.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NA</Initials>
                  <FamilyName>Dawson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1025</FirstPage>
                <LastPage>1033</LastPage>
                <Occurrence Type="PID">
                  <Handle>15020604</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXptlCkurc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.06.037</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22(6):1025–1033.</BibUnstructured>
            </Citation>
            <Citation ID="CR101_5">
              <CitationNumber>101.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Attard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Reid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Yap</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>28</IssueID>
                <FirstPage>4563</FirstPage>
                <LastPage>4571</LastPage>
                <Occurrence Type="PID">
                  <Handle>18645193</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXht1KqtLbF</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.15.9749</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Attard G, Reid AH, Yap TA et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28):4563–4571.</BibUnstructured>
            </Citation>
            <Citation ID="CR102_5">
              <CitationNumber>102.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>O’Donnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Judson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Dowsett</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2317</FirstPage>
                <LastPage>2325</LastPage>
                <Occurrence Type="PID">
                  <Handle>15150570</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Donnell A, Judson I, Dowsett M et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90(12):2317–2325.</BibUnstructured>
            </Citation>
            <Citation ID="CR103_5">
              <CitationNumber>103.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Alen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Verhoeven</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Rombauts</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Peeters</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>6085</FirstPage>
                <LastPage>6097</LastPage>
                <Occurrence Type="PID">
                  <Handle>10454556</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXlslWjs7o%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1128/MCB.19.9.6085</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 1999; 19(9):6085–6097.</BibUnstructured>
            </Citation>
            <Citation ID="CR104_5">
              <CitationNumber>104.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Chmelar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Buchanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EF</Initials>
                  <FamilyName>Need</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Tilley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen receptor coregulators and their involvement in the development and progression of prostate cancer</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>120</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>719</FirstPage>
                <LastPage>733</LastPage>
                <Occurrence Type="PID">
                  <Handle>17163421</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1elsb0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.22365</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007; 120(4):719–733.</BibUnstructured>
            </Citation>
            <Citation ID="CR105_5">
              <CitationNumber>105.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>4315</FirstPage>
                <LastPage>4319</LastPage>
                <Occurrence Type="PID">
                  <Handle>11389051</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktlSquro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61(11):4315–4319.</BibUnstructured>
            </Citation>
            <Citation ID="CR106_5">
              <CitationNumber>106.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IU</Initials>
                  <FamilyName>Agoulnik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Vaid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Bingman</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>7959</FirstPage>
                <LastPage>7967</LastPage>
                <Occurrence Type="PID">
                  <Handle>16140968</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslahs78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Agoulnik IU, Vaid A, Bingman WE, III et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005; 65(17):7959–7967.</BibUnstructured>
            </Citation>
            <Citation ID="CR107_5">
              <CitationNumber>107.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Bevan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hoare</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Heery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>8383</FirstPage>
                <LastPage>8392</LastPage>
                <Occurrence Type="PID">
                  <Handle>10567563</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXns1ygtbs%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1128/MCB.19.12.8383</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999; 19(12):8383–8392.</BibUnstructured>
            </Citation>
            <Citation ID="CR108_5">
              <CitationNumber>108.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IU</Initials>
                  <FamilyName>Agoulnik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Vaid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakka</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>10594</FirstPage>
                <LastPage>10602</LastPage>
                <Occurrence Type="PID">
                  <Handle>17079484</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFGjsrfL</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-1023</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Agoulnik IU, Vaid A, Nakka M et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006; 66(21):10594–10602.</BibUnstructured>
            </Citation>
            <Citation ID="CR109_5">
              <CitationNumber>109.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Zhou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Luo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">SRC-3 is required for prostate cancer cell proliferation and survival</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>7976</FirstPage>
                <LastPage>7983</LastPage>
                <Occurrence Type="PID">
                  <Handle>16140970</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslahs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhou HJ, Yan J, Luo W et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005; 65(17):7976–7983.</BibUnstructured>
            </Citation>
            <Citation ID="CR110_5">
              <CitationNumber>110.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Miyamoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>95</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>7379</FirstPage>
                <LastPage>7384</LastPage>
                <Occurrence Type="PID">
                  <Handle>9636157</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXktFCht7Y%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.95.13.7379</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A 1998; 95(13):7379–7384.</BibUnstructured>
            </Citation>
            <Citation ID="CR111_5">
              <CitationNumber>111.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Halkidou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VJ</Initials>
                  <FamilyName>Gnanapragasam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PB</Initials>
                  <FamilyName>Mehta</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>2466</FirstPage>
                <LastPage>2477</LastPage>
                <Occurrence Type="PID">
                  <Handle>12717424</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjt1alsL0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1206342</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Halkidou K, Gnanapragasam VJ, Mehta PB et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003; 22(16):2466–2477.</BibUnstructured>
            </Citation>
            <Citation ID="CR112_5">
              <CitationNumber>112.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Ngan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hashimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZQ</Initials>
                  <FamilyName>Ma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>734</FirstPage>
                <LastPage>739</LastPage>
                <Occurrence Type="PID">
                  <Handle>12569365</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXoslOltg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1206121</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003; 22(5):734–739.</BibUnstructured>
            </Citation>
            <Citation ID="CR113_5">
              <CitationNumber>113.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HV</Initials>
                  <FamilyName>Heemers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Sebo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Debes</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen deprivation increases p300 expression in prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>3422</FirstPage>
                <LastPage>3430</LastPage>
                <Occurrence Type="PID">
                  <Handle>17409453</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksVGksbo%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-2836</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heemers HV, Sebo TJ, Debes JD et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007; 67(7):3422–3430.</BibUnstructured>
            </Citation>
            <Citation ID="CR114_5">
              <CitationNumber>114.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SS</Initials>
                  <FamilyName>Taneja</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NK</Initials>
                  <FamilyName>Swenson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">ART-27, an androgen receptor coactivator regulated in prostate development and cancer</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>279</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>13944</FirstPage>
                <LastPage>13952</LastPage>
                <Occurrence Type="PID">
                  <Handle>14711828</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXis1eltrw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M306576200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taneja SS, Ha S, Swenson NK et al. ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 2004; 279(14):13944–13952.</BibUnstructured>
            </Citation>
            <Citation ID="CR115_5">
              <CitationNumber>115.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Fujimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Kang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>274</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>8316</FirstPage>
                <LastPage>8321</LastPage>
                <Occurrence Type="PID">
                  <Handle>10075738</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitFSrsb0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.274.12.8316</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fujimoto N, Yeh S, Kang HY et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999; 274(12):8316–8321.</BibUnstructured>
            </Citation>
            <Citation ID="CR116_5">
              <CitationNumber>116.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Guo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>15426</FirstPage>
                <LastPage>15431</LastPage>
                <Occurrence Type="PID">
                  <Handle>11856738</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xjs1Squr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M111218200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang X, Yang Y, Guo X et al. Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 2002; 277(18):15426–15431.</BibUnstructured>
            </Citation>
            <Citation ID="CR117_5">
              <CitationNumber>117.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Voeller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CI</Initials>
                  <FamilyName>Truica</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Beta-catenin mutations in human prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>2520</FirstPage>
                <LastPage>2523</LastPage>
                <Occurrence Type="PID">
                  <Handle>9635571</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXktVajt70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58(12):2520–2523.</BibUnstructured>
            </Citation>
            <Citation ID="CR118_5">
              <CitationNumber>118.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Chesire</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Ewing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Sauvageot</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Bova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Detection and analysis of beta-catenin mutations in prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>45</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>323</FirstPage>
                <LastPage>334</LastPage>
                <Occurrence Type="PID">
                  <Handle>11102958</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXovF2qs78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0045(20001201)45:4&lt;323::AID-PROS7&gt;3.0.CO;2-W</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45(4):323–334.</BibUnstructured>
            </Citation>
            <Citation ID="CR119_5">
              <CitationNumber>119.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Watanabe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kakiuchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kato</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">APC gene mutations in human prostate cancer</ArticleTitle>
                <JournalTitle>Jpn J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>77</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>8609698</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK287osFajsQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/oxfordjournals.jjco.a023188</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Watanabe M, Kakiuchi H, Kato H et al. APC gene mutations in human prostate cancer. Jpn J Clin Oncol 1996; 26(2):77–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR120_5">
              <CitationNumber>120.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Gerstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Almeida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers</ArticleTitle>
                <JournalTitle>Genes Chromosomes Cancer</JournalTitle>
                <VolumeID>34</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>9</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>11921277</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjtFWjurc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/gcc.10037</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gerstein AV, Almeida TA, Zhao G et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002; 34(1):9–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR121_5">
              <CitationNumber>121.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Henrique</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FR</Initials>
                  <FamilyName>Ribeiro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Fonseca</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>6122</FirstPage>
                <LastPage>6129</LastPage>
                <Occurrence Type="PID">
                  <Handle>17947477</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFygs7fL</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-1042</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Henrique R, Ribeiro FR, Fonseca D et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007; 13(20):6122–6129.</BibUnstructured>
            </Citation>
            <Citation ID="CR122_5">
              <CitationNumber>122.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Mulholland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Dedhar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>329</FirstPage>
                <LastPage>337</LastPage>
                <Occurrence Type="PID">
                  <Handle>16421604</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xlt1ehsQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1209020</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25(3):329–337.</BibUnstructured>
            </Citation>
            <Citation ID="CR123_5">
              <CitationNumber>123.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Rubinfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Albert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Porfiri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Fiol</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Munemitsu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Polakis</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>272</VolumeID>
                <IssueID>5264</IssueID>
                <FirstPage>1023</FirstPage>
                <LastPage>1026</LastPage>
                <Occurrence Type="PID">
                  <Handle>8638126</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjtVejsrs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.272.5264.1023</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272(5264):1023–1026.</BibUnstructured>
            </Citation>
            <Citation ID="CR124_5">
              <CitationNumber>124.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Rios-Doria</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kuefer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Ethier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Day</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Cleavage of beta-catenin by calpain in prostate and mammary tumor cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>7237</FirstPage>
                <LastPage>7240</LastPage>
                <Occurrence Type="PID">
                  <Handle>15492240</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXosFynt78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-1048</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rios-Doria J, Kuefer R, Ethier SP, Day ML. Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. Cancer Res 2004; 64(20):7237–7240.</BibUnstructured>
            </Citation>
            <Citation ID="CR125_5">
              <CitationNumber>125.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CI</Initials>
                  <FamilyName>Truica</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Byers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Beta-catenin affects androgen receptor transcriptional activity and ligand specificity</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>4709</FirstPage>
                <LastPage>4713</LastPage>
                <Occurrence Type="PID">
                  <Handle>10987273</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmsFWiu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60(17):4709–4713.</BibUnstructured>
            </Citation>
            <Citation ID="CR126_5">
              <CitationNumber>126.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sharma</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Linking beta-catenin to androgen-signaling pathway</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>11336</FirstPage>
                <LastPage>11344</LastPage>
                <Occurrence Type="PID">
                  <Handle>11792709</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xis1KgsL0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M111962200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yang F, Li X, Sharma M et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277(13):11336–11344.</BibUnstructured>
            </Citation>
            <Citation ID="CR127_5">
              <CitationNumber>127.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Mulholland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Reid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Rennie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>17933</FirstPage>
                <LastPage>17943</LastPage>
                <Occurrence Type="PID">
                  <Handle>11856748</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XktVKisLc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M200135200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002; 277(20):17933–17943.</BibUnstructured>
            </Citation>
            <Citation ID="CR128_5">
              <CitationNumber>128.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Pawlowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Ertel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Allen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <IssueID>23</IssueID>
                <FirstPage>20702</FirstPage>
                <LastPage>20710</LastPage>
                <Occurrence Type="PID">
                  <Handle>11916967</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XkslWgu7o%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M200545200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pawlowski JE, Ertel JR, Allen MP et al. Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 2002; 277(23):20702–20710.</BibUnstructured>
            </Citation>
            <Citation ID="CR129_5">
              <CitationNumber>129.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Song</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Herrell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Byers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Shah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1674</FirstPage>
                <LastPage>1687</LastPage>
                <Occurrence Type="PID">
                  <Handle>12588987</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhs1Sgs74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/MCB.23.5.1674-1687.2003</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003; 23(5):1674–1687.</BibUnstructured>
            </Citation>
            <Citation ID="CR130_5">
              <CitationNumber>130.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Song</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Interaction of {beta}-Catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>280</VolumeID>
                <IssueID>45</IssueID>
                <FirstPage>37853</FirstPage>
                <LastPage>37867</LastPage>
                <Occurrence Type="PID">
                  <Handle>16141201</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtF2is77M</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M503850200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Song LN, Gelmann EP. Interaction of {beta}-Catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem 2005; 280(45):37853–37867.</BibUnstructured>
            </Citation>
            <Citation ID="CR131_5">
              <CitationNumber>131.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Liao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LY</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>278</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>5052</FirstPage>
                <LastPage>5061</LastPage>
                <Occurrence Type="PID">
                  <Handle>12441355</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhtVKlt78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M206374200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liao G, Chen LY, Zhang A et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003; 278(7):5052–5061.</BibUnstructured>
            </Citation>
            <Citation ID="CR132_5">
              <CitationNumber>132.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Song</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Coghlan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>70</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>14593076</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjsVCisw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2003-0189</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004; 18(1):70–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR133_5">
              <CitationNumber>133.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Masiello</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>2388</FirstPage>
                <LastPage>2401</LastPage>
                <Occurrence Type="PID">
                  <Handle>15256534</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXotFamsLk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2003-0436</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Masiello D, Chen SY, Xu Y et al. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 2004; 18(10):2388–2401.</BibUnstructured>
            </Citation>
            <Citation ID="CR134_5">
              <CitationNumber>134.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Hodgson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Astapova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AN</Initials>
                  <FamilyName>Hollenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>8388</FirstPage>
                <LastPage>8395</LastPage>
                <Occurrence Type="PID">
                  <Handle>17804755</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXpvFKisro%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-0617</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007; 67(17):8388–8395.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
